Novartis - Providence Business News

Home Tags Novartis

A SLATER TECHNOLOGY FUND-backed company, Cadent Therapeutics, has entered into an agreemnt to be acquired by Novartis in a deal worth up to $770 million.

Slater Technology Fund-backed company to be acquired by Novartis

Entrepreneurship 12/18/2020

PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to...

DRUGMAKERS ARE PREPARING to raise prices Jan. 1 following promises that they wouldn’t raise their prices in 2018. / BLOOMBERG NEWS FILE PHOTO/KIYOSHI OTA

Pharma prepares to raise prices in 2019 with a wink to...

Government 12/20/2018

NEW YORK - Drugmakers are getting ready to raise prices Jan. 1 on a broader swath of medicines than in prior years, according to Bernstein...

A DIAGRAM showing the difference between a healthy brain and one with advanced Alzheimer's disease. / COURTESY NATIONAL INSTITUTES OF HEALTH

Butler Hospital, Rhode Island Mood & Memory Research Institute join Alzheimer’s...

Health Services 12/14/2017

PROVIDENCE — Butler Hospital’s Memory and Aging Program and the Rhode Island Mood & Memory Research Institute are participating in Novartis Pharmaceuticals’ international Alzheimer’s disease prevention...

MACHINE PREP: Dr. Ling Zhang, left, and Dr. Gregory D. Jay, owner of Lubris LLC, prepare the AKTA machine to purify antibodies at the Lubris lab. Lubris has licensed the glycoprotein lubricin to Novartis to use as a dry-eye treatment. / PBN PHOTO/ RUPERT WHITELEY

Lifespan researcher scores commercial hit with biolubricant Novartis deal

Health Services 11/17/2017

Dr. Gregory D. Jay, owner of Lubris LLC, is celebrating his company’s licensing of lubricin as a clinically superior dry-eye treatment to Novartis, which...

- Featured Event -

Latest News

SUBSCRIBE TO

PBN's All Access Subscription

PBN subscribers get ahead with unlimited access to PBN news, information, and insights from our editorial team, research and data, webinars and much more.